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Abstract
We review the putative functions and malfunctions of proteins encoded by genes mutated in
Charcot-Marie-Tooth disease (CMT; inherited motor and sensory neuropathies) in normal and
affected peripheral nerves. Some proteins implicated in demyelinating CMT, peripheral myelin pro-
tein 22, protein zero (P0), and connexin32 (Cx32/GJB1) are crucial components of myelin. Periaxin
is involved in connecting myelin to the surrounding basal lamina. Early growth response 2 (EGR2)
and Sox10 are transcriptional regulators of myelin genes. Mutations in the small integral membrane
protein of lysosome/late endosome, the myotubularin-related protein 2 (MTMR2), and
MTMR13/set-binding factor 2 are involved in vesicle and membrane transport and the regulation
of protein degradation. Pathomechanisms related to alterations of these processes are a widespread
phenomenon in demyelinating neuropathies because mutations of myelin components may also
affect protein biosynthesis, transport, and/or degradation. Related disease mechanisms are also
involved in axonal neuropathies although there is considerably more functional heterogeneity. Some
mutations, most notably in P0, GJB1, ganglioside-induced differentiation-associated protein 1
(GDAP1), neurofilament light chain (NF-L), and dynamin 2 (DNM2), can result in demyelinating
or axonal neuropathies introducing additional complexity in the pathogenesis. Often, this relates
to the intimate connection between Schwann cells and neurons/axons leading to axonal damage
even if the mutation-caused defect is Schwann-cell-autonomous. This mechanism is likely for P0
and Cx32 mutations and provides the basis for the unifying hypothesis that also demyelinating
neuropathies develop into functional axonopathies. In GDAP1 and DNM2 mutants, both Schwann
cells and axons/neurons might be directly affected. NF-L mutants have a primary neuronal defect
but also cause demyelination. The major challenge ahead lies in determining the individual con-
tributions by neurons and Schwann cells to the pathology over time and to delineate the detailed
molecular functions of the proteins associated with CMT in health and disease.
doi: 10.1385/NMM:8:1–2:217
Index Entries: Hereditary neuropathies; myelin; axon; Schwann cell.
NeuroMolecular Medicine
Copyright © 2006 Humana Press Inc.
All rights of any nature whatsoever reserved.
ISSN0895-8696/06/08:217–242/$30.00
doi: 10.1385/NMM:8:1–2:217
NeuroMolecular Medicine 217 Volume 8, 2006
*Author to whom all correspondence and reprint requests should be addressed. E-mail: usuter@cell.biol.ethz.ch
The authors Niemann and Berger contributed equally to this work.
218 Niemann et al.
NeuroMolecular Medicine Volume 8, 2006
Introduction
Myelin in the peripheral nervous system is gen-
erated and maintained by myelinating Schwann
cells. This highly specialized cell type enwraps seg-
ments of axons with multiple layers of its plasma
membrane. The resulting myelin sheath, together
with the highly specialized nodes of Ranvier that
are regularly arrayed along the myelinated fibers,
is responsible for efficient and rapid propagation of
action potentials along the nerve. Within this exquis-
itely regulated system, axons (neurons) and
Schwann cells are anatomically and functionally
closely connected and tightly regulate each other.
At early stages in development, Schwann-cell pre-
cursors are dependent on axonal signals for sur-
vival and proliferation to ensure that the numbers
of Schwann cells and axons are precisely matched.
Later, axons are the main determinant of the myeli-
nating phenotype when Schwann cells undergo dif-
ferentiation into myelinating and nonmyelinating
populations (Jessen and Mirsky, 1999, 2002;
Michailov et al., 2004). Myelinating Schwann cells,
in turn, have a profound effect on axonal proper-
ties (Arroyo and Scherer, 2000; Jessen and Mirsky,
2002; Poliak and Peles, 2003; Salzer, 2003; Edgar and
Garbern, 2004). During myelination in development
or remyelination after injury, juxtacrine signals from
Schwann cells mediate the sequential assembly of
multiprotein complexes of cell adhesion molecules,
ion channels, and scaffolding proteins into distinct
domains that are localized around the node of Ran-
vier. In addition, the axon cytoskeleton, organelle
content, and rates of axonal transport are tightly
regulated by myelinating Schwann cells. 
The dialog between Schwann cells and the accom-
panying axons is continuous. Neurons or Schwann
cells provide individually the “initial trigger” in reg-
ulatory events but this first stimulus is immediately
followed by signal transduction events that mediate
reciprocal interactions between the two cell types.
Consequently, Schwann cells and axons/neurons
need to be viewed as an intensely communicating
dynamic community. Breakdown of this elaborate
system results usually in peripheral neuropathies.
Hereditary neuropathies are genetically heteroge-
neous and affect neurons and/or Schwann cells. In
the Charcot-Marie-Tooth disease (CMT) group, muta-
tions in several different genes cause similar disease
phenotypes. Conversely, different mutations affecting
the same gene can lead to different disease pheno-
types (Fig. 1, reviewed by Suter and Scherer, 2003;
for an updated list of genes and mutations found in
CMT as well as the literature references to the indi-
vidual mutations, seehttp://www.molgen.ua.ac.be/
CMTMutations/default.cfm. For classification of
CMT and the associated phenotypes, see
http://www.neuro.wustl. edu/neuromuscular/
time/hmsn.html). In demyelinating neuropathies, it
is generally assumed that the defect starts in Schwann
cells causing dys- and/or demyelination, which in
turn leads to length-dependent axonal loss. Impor-
tantly, alterations or lack of the myelin sheath have
pronounced effects on the axonal caliber, phospho-
rylation, and packing of neurofilaments, axonal trans-
port, and the organization of ion channels in the
axonal membranes (Martini, 2001). Defective axonal
transport is the most likely hypothesis to explain the
observation that axonal degeneration is maximal at
distal nerve endings. Axonal transport is so crucial
owing to the extreme polarity and size of motor and
sensory neurons that, in humans, may extend for a
meter or more. Most axonal components, including
the cytoskeletal proteins, synaptic vesicle precursors,
and organelles like mitochondria must be transported
along the axon. This system must function efficiently
and is delicately sensitive to deleterious influences
of demyelination in demyelinating neuropathies or
mutated proteins in axonal neuropathies with a pri-
mary neuronal defect. Defects in axonal transport
have not only been put forward as a general critical
component of the disease mechanisms in hereditary
neuropathies (reviewed by Suter and Scherer, 2003),
but also in conjunction with other neurodegenera-
tive diseases, including amyotrophic lateral sclero-
sis and Alzheimer’s disease (reviewed by Roy and
Rauk, 2005).
Mutated Myelin Components 
in Demyelinating CMT
Even before the first genes involved in CMT were
identified, it was obvious that mutations affecting
structural and functional components of the myelin
sheath would be interesting candidates for causing
demyelinating forms of neuropathies. Indeed, muta-
tions involving four myelin-associated proteins,
peripheral myelin protein 22 (PMP22), protein zero
(P0/MPZ), connexin32 (Cx32/GJB1), and periaxin
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(PRX) have been discovered in CMT (Fig. 2,
reviewed by Suter and Scherer, 2003). 
P0/MPZ and PMP22
P0/MPZ and PMP22 are components of compact
myelin and play major structural roles in this highly
organized configuration. P0/MPZ is a single-pass
transmembrane protein with an immunoglobulin-
like domain and accounts for approx 50% of the pro-
tein content of peripheral myelin. As predicted by
its domain structure, P0/MPZ acts as an adhesion
protein connecting adjacent myelin lamellae. These
functions have been verified in vitro and in mice
with altered P0/MPZ levels (Giese et al., 1992;
Martini et al., 1995; Yin et al., 2000). Notably, over-
expression as well as haploinsufficiency leads to
myelin deficits. Both, the extracellular and the highly
positively charged cytoplasmic domains of P0/MPZ
are required for the adhesive function (Filbin et al.,
1999). Structural analysis of the extracellular domain
of P0/MPZ indicates tetrameric homophilic adhe-
sion as the main underlying molecular mechanism
(Shapiro et al., 1996).
P0/MPZ mutations cause dominant demyeli-
nating, dominant axonal, and intermediate forms
by various mechanisms. A comprehensive analysis
revealed that P0/MPZ mutations are clustered in
two major groups in relation to the associated phe-
notypes (Shy, 2004). Severe phenotypes are owing
to mutations that are predicted to affect primarily
myelin compaction owing to disruption of the struc-
ture of P0/MPZ. These mutations appear to affect
the myelination process during development and
cause early onset neuropathy. Two main mecha-
nisms are involved. Either the mutated P0/MPZ
protein is not transported within the cell to the
plasma membrane, or the mutated protein is incor-
porated into myelin but disrupts this structure, pre-
sumably by dominant-negative interactions
between the mutated and wild-type P0/MPZ pro-
tein (Previtali et al., 2000; Shames et al., 2003; Shy,
2004). Asecond group of P0/MPZ mutations affects
predominantly axons and causes a late-onset neu-
ropathy. The corresponding pathomechanisms are
less obvious because P0/MPZ expression is con-
fined to Schwann cells. The hypothesis has been put
forward that subtle myelin alterations, owing to the
Fig. 1. Schematic overview highlighting proteins that are mutated in CMT. The localization of the normal proteins
is depicted. Proteins have been assigned to Schwann cells and/or neurons, respectively, when expression and the
observed form of CMT overlap.
220 Niemann et al.
NeuroMolecular Medicine Volume 8, 2006
incorporation of the mutant P0/MPZ protein, affect
Schwann cell–neuron interactions leading to axonal
damage and loss (Shy, 2004). However, the nature
of the exchanged signals is not known at this time.
Identifying them is an exciting task for the future.
P0/MPZ has also been suggested to interact with
PMP22 to enforce adhesive interactions (Fig. 1;
D’Urso et al., 1999; Hasse et al., 2004). This is con-
sistent with the finding that both proteins are spa-
tially and temporally coexpressed during
development and in the adult (Hagedorn et al.,
1999; Notterpek et al., 1999). PMP22 is a glycosy-
lated membrane component that is commonly
referred to as a four-transmembrane protein
although alternative membrane topologies remain
to be considered as long as direct structural data
are not available (Taylor et al., 2000). PMP22
accounts for 2–5% of the myelin protein content
and tends to oligomerize (Snipes et al., 1992; Tobler
et al., 1999, 2002; Liu et al., 2004). Besides its struc-
tural role in myelin, PMP22 regulates cell spread-
ing, cell migration, and apoptosis (Fabbretti et al.,
1995; Brancolini et al., 1999, 2000; Sancho, et al.,
2001; Roux et al., 2005). PMP22 is also an early con-
stituent of the developing blood–nerve and blood–
brain barriers at intercellular junctions (Notterpek
et al., 2001; Roux et al., 2004), a finding that is likely
to be functionally related to the observation that
PMP22 can modulate epithelial morphology and
monolayer permeability in cell culture (Roux et al.,
2005). In vivo, a functional requirement for PMP22
in junction complexes remains to be established.
Mice lacking PMP22 are not obviously affected in
epithelia integrity but show a mildly delayed onset
of myelination indicating some crucial function of
PMP22 in the initial steps of myelination (Carenini
et al., 1999). Later, characteristic focal hypermyeli-
nating structures (called tomacula = sausage) are
formed, which degenerate with progressing age
and remodel the Schwann cell and axonal protein
composition by demyelination (Adlkofer et al.,
1995; Neuberg et al., 1999). Thus, PMP22 is indis-
pensable for proper myelination and myelin main-
tenance in peripheral nerves whereas in other
tissues, PMP22 function is likely compensated by
other members of the PMP22/EMP/MP20 family
(Jetten and Suter, 2000). Heterozygous PMP22-null
mice revealed haploinsufficiency and mimic genet-
ically, behaviorally, and morphologically the
peripheral nerve disorder hereditary neuropathy
with liability to pressure palsies (HNPP; Adlkofer
et al., 1997). HNPP is a recurrent neuropathy that is
Fig. 2. Proteins involved in the formation of the Schwann-cell myelin sheath.
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precipitated by minor trauma to peripheral nerves
with tomacula as typical morphological feature
(Lupski and Chance, 2005). The cellular mechanisms
that cause these particular myelin outfoldings have
yet to be determined.
Heterozygous intrachromosomal duplication of
a segment containing the PMP22 gene on chromo-
some 17p11 is associated with the by far most
common form of inherited form of demyelinating
neuropathies (CMT1A; reviewed by Saifi et al.,
2003). Transgenic experiments in rodents have
definitively established that PMP22 is the disease-
causing gene (Huxley et al., 1996; Magyar et al.,
1996; Sereda et al., 1996). However, the causative
cellular mechanisms of the disease are still largely
mysterious. It has been argued that PMP22 may be
required in precise stoichiometric amounts in
myelin. This hypothesis remains still plausible
(Suter and Snipes, 1995). Alternatively, PMP22 over-
expression might affect Schwann-cell physiology in
more general ways (reviewed by Suter, 2004). 
Recently, altered intracellular membrane trans-
port and defects in protein degradation have been
implicated in the disease process. Newly synthe-
sized PMP22 has a short half-life within the myeli-
nating Schwann cell (Pareek et al., 1993, 1997) and
most of the protein is rapidly degraded via the
ubiquitin–proteasome pathway before reaching the
Schwann-cell plasma membrane (Notterpek et al.,
1999; Ryan et al., 2002). This could be interpreted
that the intracellular processing and transport
machinery is already operating at the limit of its
capabilities with respect to PMP22 biosynthesis.
PMP22 overexpression in CMT1A may now over-
load this fine-tuned system. Proteasomal degrada-
tion is one of the possibly associated and damaged
processes. This hypothesis is consistent with the
finding that overexpression of PMP22 causes intra-
cellular accumulation in vacuolar structures in vitro,
but most notably also in PMP22-overpressing rats
(Niemann et al., 2000; Chies et al., 2003). Experi-
ments aimed at dissecting the underlying mecha-
nisms revealed that PMP22 overexpression induces
the formation of microtubule (MT)-dependent ubiq-
uitinated PMP22 aggregates called aggresomes
(Ryan et al., 2002). These structures as well as PMP22
overexpression-induced myelin-like intracellular
figures are closely related (Dickson et al., 2002; Chies
et al., 2003). Both are likely to be degraded by the
process of autophagy (Fortun et al., 2003). Taken
together, PMP22 overexpression appears to affect
intracellular degradation of membrane components,
including PMP22 itself, suggesting a pathomech-
anism that may also include aberrant turnover of
other proteins or even lipids. Asecond major, seem-
ingly unrelated, pathway of intracellular membrane
transport is also affected. On overexpression, PMP22
induces the formation of and accumulates in actin/
phosphatidylinositol (4,5)-bisphosphate (PI-4,5-P2)-
positive vacuoles (Chies et al., 2003). This results in
trapping of membrane proteins by altering ADP-
ribosylation factor-6 (Arf6)-regulated endoso-
mal–plasma membrane recycling. Although
appealing, the distinct contributions of these altered
biosynthetic pathways to the development of
demyelinating neuropathies remain largely unclear.
Besides increased PMP22 gene dosage, PMP22
missense mutations are associated with myelina-
tion defects. The vast majority of the mutations are
dominantly inherited, affect hydrophobic domains
of the protein, and lead to more severe phenotypes
compared with PMP22 overexpression, often
referred to Dejerine-Sottas syndrome (reviewed by
Saifi et al., 2003). The mutant proteins fail to reach
the cell surface owing to retention in the endoplas-
mic reticulum (ER) or in the intermediate compart-
ment (Naef et al., 1997; D’Urso et al., 1998; Naef and
Suter, 1999; Tobler et al., 1999; Colby et al., 2000;
Shames et al., 2003). Because mutant PMP22 and
wild-type PMP22 can form homo- and heterodimers
and multimers (Tobler et al., 1999, 2002), the retained
mutant may block a proportion of wild-type PMP22
from transport to the cell membrane by a dominant-
negative mechanism. However, genetic evidence
suggests that at least in some mutants, such a mech-
anism is unlikely to be exclusively responsible for
the pathology because some mutated PMP22 pro-
teins exert a deleterious effect in the absence of wild-
type PMP22 (Adlkofer et al., 1997). Several potential
mechanisms could explain such a “toxic gain-of-
function” of mutated PMP22. First, PMP22 inter-
acts with P0 opening the possibility of a
trans-dominant effect of PMP22 mutants on the traf-
ficking of P0 and vice versa. Interactions between
the two proteins during intracellular trafficking,
however, are limited, rendering such a patho-
mechanism unlikely (Shames et al., 2003). Second,
increased association of mutated and ER-retained
PMP22 with calnexin may lead to a deleterious
sequestration of this ER-resident chaperon, causing
222 Niemann et al.
NeuroMolecular Medicine Volume 8, 2006
a more general defect in protein biosynthesis
(Dickson et al., 2002). Third, accumulation of mutant
PMP22 could trigger the unfolded protein response
in the ER (as suggested for retained proteolipid pro-
tein [PLP] mutants [Southwood et al., 2002]) but
experimental support for such a signaling is miss-
ing. Interestingly, in contrast to the dominantly
inherited mutations, the few recessive PMP22 muta-
tions have a low potential for aggregation and are
transported to the cell surface, leaving clues toward
the associated disease mechanisms largely in the
dark (Liu et al., 2004).
The availability of animal models carrying PMP22
missense mutations (Suter et al., 1992a,b; Isaacs
et al., 2002) has revealed additional insights into
the pathomechanisms. The endosomal–lysosomal
pathway (Notterpek et al., 1997) and ubiquitination
(Ryan et al., 2002) are upregulated and PMP22-
containing aggresomes (Notterpek et al., 1999;
Ryan et al., 2002) and myelin-like figures (Dickson
et al., 2002), most likely representing autophagic
vacuoles (Dunn, 1990) are present in mutant
Schwann cells. Because aggresomes are eventually
degraded by lysosomes, these observations reflect
probably alterations within the same pathway
(Fortun et al., 2003). Interestingly, impaired pro-
teasome activity and accumulation of ubiquitinated
substrates, including PMP22, has been observed in
the mutant PMP22 animals (Fortun et al., 2005), sug-
gesting that aggresome formation is likely to be
deleterious in this setting and does not have a bene-
ficial effect in removing potentially toxic misfolded
PMP22 (Isaacs et al., 2002).
In summary, remarkable progress has been
made in defining the cellular and molecular mech-
anisms underlying PMP22-based neuropathies
suggesting a variety of general and Schwann-cell-
specific potential cellular disease mechanisms,
ranging from abnormal biosynthesis to abnormal
protein processing and degradation, abnormal tar-
geting to myelin, induction of apoptosis, and
abnormal function in myelin (Muller, 2000). The
challenge remains to determine how these effects
are related and connected as well as to assign and
determine their individual contributions to the
disease. Aparticularly pressing issue concerns the
interrelationship between the disease mechanisms
of PMP22 overexpression compared with PMP22
point mutations. Is there a general disease 
mechanism, or are specific elements involved
depending on the nature of the mutation? Recent
evidence from transcriptional profiling suggests
that both common and specific factors play a role
in the pathomechanisms associated with altered
PMP22 expression or PMP22 mutations (Giambonini-
Brugnoli et al., 2005). Indirect support for poten-
tially diverging disease mechanisms is also
provided by earlier studies demonstrating that the
effects of PMP22 overexpression on cell spread-
ing and apoptosis require cell surface expression
of PMP22 (Brancolini et al., 2000). Because disease-
associated dominant PMP22 missense mutants are
not transported to the plasma membrane they
cannot influence these processes. In addition, a
CMT1A-associated PMP22 mutant was unable to
trigger the formation of PI-4,5-P2-positive vacuoles
(Chies et al., 2003). Further elucidation of these
issues, in particular, determining which of the
described effects contribute indeed to the CMT
pathology caused by a particular PMP22 alteration
(Shames et al., 2003; Suter, 2004), will be of major
importance for understanding the basic mechanisms
underlying the most common form of hereditary
neuropathies.
Connexin32
Mutations in the gap junction protein Cx32/GJB1
cause the X-chromosome linked CMT1X. Connex-
ins are tetraspan proteins that oligomerize to form
hemichannels in cell membranes. Two hemichan-
nels on apposing membranes form a gap junction.
The resulting, highly regulated pore permits the
transport of small molecules (usually smaller than
1 kDa) across membranes. In myelin of peripheral
nerves, Cx32/GJB1 is present in Schmidt-Lanter-
mann incisures, paranodal loops, and at the intern-
odal zone of partial myelin compaction (Meier et al.,
2004). It is generally assumed that the formed gap
junctions provide a critical radial pathway directly
through the myelin sheath. Disruption of this radial
pathway by Cx32/GJB1 mutations may then cause
demyelination. Alternatively or concomitantly,
alterations of the Cx32/GJB1-based gap junctions
between compact and uncompact myelin may con-
tribute to the disease. In any case, the nature of the
critical molecules that are exchanged through
Cx32/GJB1-specific channels is unclear because
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general dye transfer is still possible through gap
junctions in incisures of Cx32/GJB1-deficient nerves
(Balice-Gordon et al., 1998). 
Cx32/GJB1 mutations are spread over the entire
protein and cause rather homogeneous disease
characteristics. Affected males have a demyeli-
nating phenotype with more pronounced axonal
loss than in CMT1A. Experiments in transgenic
mice indicate that the initial disease-causing defect
occurs in myelinating Schwann cells and axonal
loss is secondary (Scherer et al., 2005). Affected
women show a variable phenotype, probably pro-
portional to the number of myelinating Schwann
cells that inactivate the normal Cx32/GJB1 allele
by X-chromosome inactivation. The uniformity of
the phenotype in CMT1X peripheral nerves sug-
gests that most Cx32/GJB1 mutants inactivate the
protein consistent with null alleles. However, the
current mechanistic knowledge is fragmentary.
Trafficking of Cx32/GJB1 mutants in mammalian
cells is often, but not in all cases, disrupted. Many
mutants form nonfunctional channels whereas
others form functional channels with altered bio-
physical characteristics. Some disease-associated
mutants form even fully functional channels
(Scherer and Paul, 2004). How these mutants cause
demyelination remains to be clarified. 
Periaxin
PRX mutations are recessively inherited and
cause a wide spectrum of demyelinating neu-
ropathies with particularly prominent sensory
involvement (reviewed in Takashima et al., 2002).
PRX is a membrane-associated protein with a PDZ
domain (named after the three proteins in which
it was first described: postsynaptic density pro-
tein-95, drosophila discs large tumor suppressor
gene (dlg) and the tight junction-associated pro-
tein ZO-1) that is involved in mediating pro-
tein–protein interactions. PRX is mainly expressed
by myelinating Schwann cells (Dytrych et al., 1998)
although it is also found prominently in junctional
complexes in the eye lens (Straub et al., 2003).
During myelination, PRX is located close to the
adaxonal membrane (near to the axon) but in
mature myelin sheaths, it has changed its local-
ization to the abaxonal membrane (near to the
basal lamina). In the adult, PRX interacts with the
dystroglycan complex through dystrophin-related
protein-2 (DRP2) and links the basal lamina to the
Schwann-cell cytoskeleton (Sherman et al., 2001).
PRX-null mice develop grossly normal myelin
fibers (Gillespie et al., 2000). However, closer
inspection revealed that cytoplasmic bands (Cajal
bands) are disrupted and Schwann-cell elonga-
tion during nerve growth is impaired (Court et al.,
2004). The resulting decreased internodal dis-
tances cause decreased nerve conduction veloci-
ties and affected motor function. The altered
myelin structure in PRX-null mice appears to be
unstable because myelin outfoldings and exten-
sive demyelination are common features in periph-
eral nerves of older animals (Gillespie et al., 2000).
How these findings are related to the broad range
of phenotypes associated with PRX mutations is
not yet clear, in particular with regard to the pro-
nounced sensory defects. PRX mutations empha-
size the general fact, however, that protein
complexes involved in extracellular matrix sig-
naling are often affected in diverse neuropathies.
This includes merosin-deficient congenital mus-
cular dystrophy, neurofibromatosis, and leprosy
(reviewed by Feltri and Wrabetz, 2005).
Proteolipid Protein
Mutations in the PLP1/DM20 gene cause the 
X-linked leukodystrophyl Pelizaeus-Merzbacher
disease (reviewed by Cailloux et al., 2000). In some
mutants, this is accompanied by a demyelinating
peripheral neuropathy (Garbern et al., 1997; Shy
et al., 2003; Vaurs-Barriere et al., 2003). PLP1/DM20,
a membrane protein with a putative tetraspan topol-
ogy, accounts for the majority of CNS myelin pro-
tein. It is also expressed by myelinating Schwann
cells and occurs in two different splice forms, PLP1
and DM20. Both proteins are identical except that
PLP1 carries a 35-amino-acid-long insertion in a
putative intracellular domain (corresponding to the
major dense line in compact myelin). PLP1-null
mutations and PLP1 truncation mutations that
affect exclusively the PLP1 isoform, but not DM20,
are associated with peripheral neuropathies (Garbern
et al., 1997; Shy et al., 2003), suggesting a requirement
for the PLP1 isoform for the proper function of
myelinated peripheral nerves. The underlying
cellular disease mechanisms in this particular
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form of neuropathy have yet to be determined (Shy
et al., 2003). 
Transcription Factors Involved 
in Myelin Gene Regulation: Early
Growth Response 2 and Sry-Related
High-Mobility Group Box-Containing
Gene 10
The exquisite gene-dosage sensitivity of
P0/MPZ and PMP22 indicates that the expression
of myelin components is tightly regulated. Thus,
transcription factors regulating genes that encode
myelin proteins are potential candidates to be
mutated in demyelinating neuropathies. In line
with this hypothesis, mutations affecting two tran-
scription factors, EGR2/Krox20 and Sox10, have
been found in CMT.
EGR2/Krox20 is a zinc finger-containing pro-
tein and null mutant mice for this protein do not
develop peripheral nerve myelin (Topilko et al.,
1994). This is consistent with several recent stud-
ies suggesting a broad function of EGR2/Krox20
in the regulation of Schwann-cell myelination by
controlling myelin protein gene expression and
cholesterol/lipid biosynthesis via the sterol regu-
latory element binding protein (SREBP) pathway
(Nagarajan et al., 2001; Parkinson et al., 2004; Le
et al., 2005a; Leblanc et al., 2005). EGR2/Krox20
mutations in human are associated with demyeli-
nating or dysmyelinated forms of CMT (CMT1D,
CMT4E, and congenital hypomyelination). Muta-
tions in the zinc finger domain lead to the domi-
nantly inherited form CMT1D. They affect DNA
binding negatively and the reduction of DNA
binding correlates with the severity of the result-
ing disease (Warner et al., 1998). Aparticular muta-
tion, located in the R1 domain of EGR2/Krox20,
may affect the interaction between EGR2/Krox20
and its coregulators, the NGFI-A-binding proteins
(NABs;Warner et al., 1998; Warner et al., 1999).
This mutation is recessively inherited and is classi-
fied as CMT4E. The underlying pathogenic mech-
anisms remain unclear because disturbed
coactivation as well as corepression of EGR2/
Krox20 by NAB proteins is conceivable (Le et al.,
2005b). Mutations in the two NAB-encoding genes
themselves have not been found in hereditary
neuropathies, most likely because the two NAB
proteins have strikingly redundant, but together,
indispensable, functions in peripheral nervous
system myelination (Le et al., 2005b).
SOX10 encodes a high-mobility group domain-
containing transcription factor (reviewed by Mol-
laaghababa and Pavan, 2003) and some mutations
in SOX10 are associated with peripheral neuropathy,
demyelinating leukodystrophy, and Waardenburg-
Hirschsprung disease (reviewed by Inoue et al.,
2002). With regard to the peripheral nervous system,
SOX10 is expressed by neural crest stem cells, the
progenitors of Schwann cells, and plays a crucial
role in progenitor cell maintenance as well as in the
control of peripheral gliogenesis (Britsch et al., 2001;
Paratore et al., 2001; Kim et al., 2003). SOX10 is a
direct transcriptional regulator of P0/MPZ and
Cx32/GJB1 providing a mechanistic link to the
pathogenesis of other demyelinating peripheral
neuropathies (Peirano and Wegner, 2000; Peirano
et al., 2000; Bondurand et al., 2001). Strikingly, two
CMT1X-causing mutations impair SOX10 func-
tion on the mutated P2 promoter of Cx32/GJB1
(Bondurand et al., 2001; Houlden et al., 2004). Con-
versely, SOX10 mutants identified in patients with
peripheral myelin defects fail to transactivate the
Cx32/GJB1 promoter. 
CMT Owing to Altered Protein
Synthesis, Sorting, and/or Degradation
The correct composition and maintenance of
membranous compartments in myelinating
Schwann cells and in neurons depend on the
equilibrium between the synthesis of structural and
signaling components and their degradation.
Membrane proteins are synthesized in the ER,
modified during their transport through the ER and
Golgi, and then either directly degraded or inserted
into the plasma membrane. Proteins are removed
from the plasma membrane by endocytosis. In a first
step, proteins are transported to early endosomes
where they are sorted according to their fate. Either
they are sent in vesicles along microtubles via late
endosomes to lysosomes for degradation, or they
recycle back to the plasma membrane (Fig. 3).
Several proteins that are directly involved in the
regulation of these processes are mutated in various
forms of CMT.
Pathomechanisms of Mutant Proteins in CMT Disease 225
NeuroMolecular Medicine Volume 8, 2006
Endocytosis and Sorting: Myotubularin-
Related Proteins 2 and 13, Dynamin 2,
Ras-Associated Protein Rab7, and N-myc
Downstream-Regulated Gene 1
Myotubularins form a large family of conserved
dual-specificity phosphatases with active and inac-
tive members that are involved in the regulation of
membrane dynamics (Wishart and Dixon, 2002).
Mutations in three genes of this family are associated
with human diseases. Mutations in myotubularin
cause X-linked myotubular myopathy and mutations
in myotubularin-related protein-2 (MTMR2) or
MTMR13/SBF2 lead to CMT4B1 or CMT4B2, respec-
tively (Laporte et al., 1996; Bolino et al., 2000;
Azzedine et al., 2003;  Senderek et al., 2003b). CMT4B1
is classified as a recessive demyelinating neuropathy
with prominent myelin outfoldings as particular
pathological feature. Consistent with this phenotype,
Schwann-cell-specific ablation of MTMR2 is sufficient
for the development of myelin outfolding in trans-
genic mice (Bolino et al., 2004; Bolis et al., 2005;
Bonneick et al., 2005). Appreciable levels of MTMR2
are also found in the axon (Berger et al., 2002) and
MTMR2 has been reported to interact with the
neurofilament light chain (NF-L; Previtali et al., 2003).
Active myotubularins dephosphorylate PI-3-P and
Pl-3,5-P2 and the disease-associated forms of MTMR2
show drastically reduced phosphatase activity toward
these substrates. Thus, loss of phosphatase activity is
likely to be involved in the pathogenic mechanism
(Walker et al., 2001; Berger et al., 2002). 
Fig. 3. Proteins related to CMT that are involved in synthesis, sorting, and degradation processes are indicated
at their subcellular localization in a schematic drawing.
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The substrate specificity of myotubularins points
to a function in the regulation of endocytosis, vesic-
ular protein sorting, and protein degradation. This
hypothesis is supported by findings that myotubu-
larin mutations block endocytosis in the coelomo-
cytes of Caenorhabditis elegans (Dang et al., 2004) and
that PI-3-P and PI-3,5-P2 are used as membrane
adaptors for proteins involved in early and late
phases of the endocytic process. PI-3-P is localized
on early endosomes and acts as an adaptor for FYVE
domain-containing proteins (Gaullier et al., 1998).
The localization and function of PI-3,5-P2 is not as
well established. PIKfyve, the kinase which phos-
phorylates PI-3-P to PI-3,5-P2 is localized on late
endosomes indicating that PI-3,5-P2 is also localized
in this compartment (Shisheva et al., 2001). MTMR2
binds to PI-3,5-P2 via its GRAM–pleckstrin homol-
ogy domain but also to other phosphoinositides.
Membrane association is achieved as a dimer and
tightly regulated. It is only observed on vacuoles
after an external activating signal whereas MTMR2
localizes to the cytosol under steady-state condi-
tions (Berger et al., 2003). MTMR2 interacts directly
with MTMR13/sbf2, providing a compelling
explanation for why mutations in MTMR2 or
MTMR13/sbf2 lead to the same pathology (Berger
et al., 2006; Robinson and Dixon, 2005). In addition,
MTMR2 binds to Dlg1/SAP97 in myelinated nerve
fibers but with unknown functional significance
(Bolino et al., 2004).
Dynamin2 (DNM2) mutations are associated with
the dominant-intermediate CMT type B (DICMTB)
(Züchner et al., 2005). Owing to the intermediate
electrophysiology and pathology of this phenotype
and the ubiquitous expression of DNM2, the dis-
ease-relevant cell type(s), neurons, and/or Schwann
cells, are not yet clear. DNM2 belongs to the family
of large GTPases. Members of this group regulate
membrane trafficking, actin-based cytoskeletal
dynamics, and membrane fission and fusion of vesi-
cles, mitochondria, and peroxisomes (Praefcke and
McMahon, 2004; McNiven, 2005). Dynamins
hydrolyze GTP to act as mechanochemical proteins
to constrict and deform membranes, including
pinching of newly formed clathrin-coated vesicles,
indicating a function in early phases of endocyto-
sis (Rappoport and Simon, 2003; Praefcke and
McMahon, 2004). All disease-associated mutations
identified so far are located in the β3/β4 loop of the
DNM2 pleckstrin-homology domain and result in
reduced binding to vesicles, reduction of receptor-
mediated endocytosis, and a striking reorganiza-
tion of the microtubular cytoskeleton (Züchner et
al., 2005). The relevance of the binding of dynamins
to MTs for cytoskeletal dynamics is controversial
but is supported by the finding that DNM2 binds
to γ-tubulin at the centrosome (Thompson et al.,
2004). However, DNM2 is definitively a key regu-
lator of actin dynamics (Buccione et al., 2004;
McNiven et al., 2004). DNM2 interacts with actin-
binding proteins including profilin, cortactin, and
Abp1 (reviewed in Orth and McNiven, 2003). This
regulates the formation of membrane tubulation,
the formation of podosomes (formation of dynamic
membrane portusions in contact to the ECM,
similar to focal adhesions), invadopodia (special-
ized podosomes which can modulate the ECM),
and circular dorsal ruffles/waves (cytoplasmatic
remodeling to allow motility in response to a
stimulus; reviewed in Buccione et al., 2004). How
and to what extent these diverse processes of endo-
cytosis, MT organization, and actin-mediated
membrane dynamics are altered by the disease-
causing mutation in neurons and/or Schwann cells
remains an open question. On a speculative note,
this mechanism may include synaptic vesicle
depletion, possibly secondary to an endocytosis
defect at the neuromuscular junction (as described
in a dynamin Drosophila mutant; reviewed by
McNiven, 2005). Deficient axonal transport or
altered polarity and organization of myelinating
Schwann cells are also conceivable pathological
consequences of DNM2 mutations (reviewed by
Scherer and Arroyo, 2002; Salzer, 2003). Elucidation
of the mechanistic basis of the dominant effect of
the identified DNM2 mutations remains another
pressing issue. 
Rab7 mutations are associated with the dominant
axonal CMT2B. This favors a neuronal disease mech-
anism (Verhoeven et al., 2003), despite the fact that
Rab7 is ubiquitously expressed and is likely to play
important roles in neurons and Schwann cells. Rab7
belongs to the large superfamily of small GTPases
that are key regulators of many aspects of membrane
transport. Rab7 binds to subdomains of early endo-
somes and escorts proteins via late endosomes to
lysosomes (Vonderheit and Helenius, 2005). Rab7
is also required for the endocytosis of glycosphin-
golipids from the plasma membrane and the trans-
port to the Golgi compartment. In Niemann-Pick
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type-C fibroblasts, high levels of glycosphingolipids
accumulate in the endocytic compartment and this
defect can be corrected by overexpression of Rab7
(Choudhury et al., 2002). This finding provides a
tantalizing link to hereditary sensory neuropathy
type 1 (HSN1) because affected patients show a
similar phenotype compared with patients with
Rab7 mutations (strong involvement of sensory
components, skin ulcers). HSN1 is caused by muta-
tions in the gene coding for subunit 1 of serine palmi-
toyltransferase, an enzyme that catalyzes a key step
of sphingolipid synthesis (Dawkins et al., 2001).
Thus, the pathogenic mechanism in CMT2B and
HSN1 might be interrelated. The disease mecha-
nisms of Rab7 may also be linked to axonal transport
because Rab7 is involved in lysosomal transport
through the effector protein RILP that induces the
recruitment of dynein–dynactin motors and dynein
mutations can result in axonal degeneration 
(see below).
Although myelin deficiencies are rare in CMT2B,
Rab7 may contribute to the phenotype by affecting
also the processing and degradation of myelin
proteins. Rab7 is involved in the regulation of the
autophagic degradation pathway that has been
suggested to play a central role in neuropathies
owing to PMP22 missense mutations or PMP22
overexpression (Gutierrez et al., 2004).
N-myc downstream-regulated gene 1 (NDRG1)
is mutated in the recessive CMT4D (LOM). NDRG1
expression is Schwann-cell-specific in peripheral
nerves (Berger et al., 2004), consistent with the
demyelinating disease caused by NDRG1 mutations
in humans and null mutations in mice (reviewed by
Hunter et al., 2003; Okuda et al., 2004). The cellular
function of NDRG1 in Schwann cells, however, is
not established, although a variety of proposals have
been made (reviewed in Berger et al., 2004). The
apolipoproteins A-I (APOA1) and A-II (APOA2) are
putative NDRG1-interacting proteins (Hunter et al.,
2005). These proteins are major components of
high-density lipoproteins that regulated lipid
distribution within the body. Because myelinating
Schwann cells have a high demand on lipids, it is
conceivable that NDRG1 mutations affect the
interactions with APOA1 or APOA2 causing
demyelination. Several additional putative NDRG1
interaction partners with various roles in intracel-
lular vesicle and membrane trafficking have been
described, providing a potential functional link to
other CMT-related proteins that play a role in such
processes (Sugiki et al., 2004; Hunter et al., 2005).
Aspartoacyclase was also found as a putative
NDRG1-binding partner (Sugiki et al., 2004). This
is intriguing because mutations in aspartoacyclase
lead to Canavan disease, a leukodystrophy that
affects the CNS myelin sheath (Kaul et al., 1993).
Sorting and Degradation: Small Integral
Membrane Protein of Lysosome/Late
Endosome
Mutations in the small integral membrane pro-
tein of lysosome/late endosome (SIMPLE/LITAF)
cause the dominant demyelinating neuropathy
CMT1C but can also be associated with axonal forms
(reviewed by Saifi et al., 2005). LITAF is a putative
E3 ubiquitin ligase of the RING finger motif-
containing E3 subfamily with several proline-rich
sequences (PY motifs) and SH2-binding motifs.
Interestingly, such elements also exist in
Krox20/EGR2 and Sox10 (Saifi et al., 2005). The first
PY motif interacts with NEDD4, a member of the
HECT domain-containing E3 ubiquitin ligase sub-
family and with WW domain oxidoreductase, a
potential tumor-supressor gene (Jolliffe et al., 2000;
Ludes-Meyers et al., 2004; Saifi et al., 2005). It has
been speculated that NEDD4 ubiquitinates
SIMPLE/LITAF, thereby enabling binding to
TSG101 (a putative E2 ubiquitin-conjugating
enzyme; Pornillos et al., 2002) and regulating endo-
somal protein sorting (Saifi et al., 2005). However,
the disease-relevance of the interactions with the
PY motif(s) requires further experimental confir-
mations because proline-rich recognitions motifs
are not always specific. SIMPLE/LITAF partially
colocalizes with WW domain oxidoreductase in the
Golgi and with LAMP-1 in lysosomes, consistent
with a functional role of LITAF in protein degrada-
tion (Moriwaki et al., 2001; Ludes-Meyers et al.,
2004). Bennett et al. (2004) suggested that
SIMPLE/LITAF mutations might affect proper
PMP22 degradation in lysosomes and have a related
mechanistic effect to PMP22 overexpression in lead-
ing to demyelinating neuropathy. Saifi et al. (2005)
postulated PMP22 as one of the substrates for a
LITAF-mediated ubiquitin-dependent pathway of
protein degradation, indirectly supported by the
finding that overexpression and point mutations
affecting PMP22 cause aggresome formation of
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ubiquitinated PMP22 aggregates (Ryan et al., 2002).
Consistent with these notions, a case of early-onset
CMT disease was recently described in a patient
with a duplication of the PMP22 gene in combi-
nation with a disease-causing mutation in the
SIMPLE/LITAF gene (Meggouh et al., 2005). A
misfunction of SIMPLE/LITAF in endosomal
sorting or lysosomal functionality may accentuate
the effects of PMP22 accumulation resulting in
severe demyelination. Taken together, the disease
mechanism associated with SIMPLE/LITAF
mutations may affect the putative SIMPLE/LITAF
ubiquitin ligase activity, alterations of interactions
with partners such as NEDD4 and/or TSG101,
and/or impaired endosomal protein trafficking
and degradation.
Glycyl-tRNA Synthetase in CMT
Mutations in the glycyl-tRNAsynthetase (GARS)
gene lead to the dominant axonal CMT2D or 
type-V distal muscular atrophy. This classification
is based on the presence or absence of sensory
changes. Patients with GARS mutations, however,
present a clinical continuum of predominantly
motor distal neuronopathy/axonopathy with
mild-to-moderate sensory involvement that varies
between the families and between members of the
same family (Sivakumar et al., 2005). GARS carries
out a ubiquitous function in cells by charging the
amino acid glycine to its cognate tRNA. It is intrigu-
ing that mutations affecting a gene that is involved
in such a general physiological function result in a
peripheral nerve-specific phenotype. Whether
loss-of-function (e.g., haploinsufficiency), gain-of-
function, or dominant-negative effects are at work
remains to be determined. Because GARS forms
oliogomers (Woese et al., 2000), dominant-negative
mechanisms are likely. However, humans have only
one known protein, GARS, which acts as glycyl
tRNA synthetase and thus, reduction of its activity
in the heterozygous state may specifically affect
motor and sensory neurons in the disease owing to
their specific metabolic requirements. Alternatively,
although less likely based on the pathology
(Sivakumar et al., 2005), Schwann cells may be
particularly vulnerable to GARS function owing to
the high metabolic demands during myelination.
In this scenario, the observed axonal loss might be
secondary to altered Schwann-cell–axon interactions.
Peripheral Neuropathies Owing 
to Altered Transport Processes 
and/or Alterations of the Cytoskeleton
Peripheral nerve fibers contain two specialized
cell types, neurons and Schwann cells, which both
show astonishing cellular morphologies. The cell
bodies of sensory and motor neurons are located in
the dorsal root ganglia and in the ventral horn of
the spinal cord, respectively. The sensory receptors
and the effector muscles lie in the periphery of the
body. This distance, which in case of the lower limbs
can easily be over 1 m, must be bridged by a con-
tinuous extension of a neuron, the axon. Crucial
cargo has to be transported along the length of the
axon forward and backward, including proteins
contained in vesicles and organelles. This requires
a highly efficient process, a fact that is underscored
by various mutations in cytoskeletal and transport
proteins found in CMT. Likewise, mutations in
proteins that affect the correct association of
organelles and vesicles with the transport machinery
are likely causes for CMT (Fig. 4). 
Neurofilaments
Neurofilaments are formed by a trimeric protein
complex that consists of the NF heavy chain (NF-H;
200 kDa), the medium chain (NF-M; 168 kDa), and
the light chain (NF-L; 62 kDa). Mutations in NF-L
are associated with dominant axonal and dominant
demylinating peripheral neuropathies. NF-L is an
abundant cytoskeletal protein in neurons (Lariviere
and Julien, 2004). Thus, the observed demyelination
is likely be the consequence of altered neuron–
Schwann-cell signaling. 
NF biosynthesis and transport within the axon is
tightly controlled. During development, increases
in NF expression, local accumulation, and estab-
lishment of proper spacing of NF control the radial
growth of the axon (Lariviere and Julien, 2004).
Specifically, the tail domain of NF-M, with seven
phosphorylated KSP motifs, is an essential target
for a myelination-dependent outside-in signaling
cascade that determines axonal caliber and con-
duction velocity (Garcia et al., 2003). This is concep-
tually important because in demyelinating
neuropathies, this signaling is presumably disturbed,
causing NF hypophosphorylation, reduced NF
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spacing, reduction in axonal transport, axonal atro-
phy, and as secondary effects, loss of axons and
muscle atrophy (Suter and Scherer, 2003). Thus, phos-
phorylation of NF appears to play a critical and broad
role in the pathogenesis of CMT that can be initiated
by neurons or Schwann-cell (myelin) defects.
Newly synthesized NF subunits are transported
from the perikaryon along MTs by motor proteins
Fig. 4. Proteins related to CMT involved in the organization of the cytoskeleton, transport and mitochondrial
dynamics are depicted in a hypothetical cell body (A) and in an axon (B).
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(Xia et al., 2003). In addition, NFs are transported
also in retrograde fashion via cytoplasmatic dynein
(LaMonte et al., 2002; Wagner et al., 2004). Whether
single or associated NF subunits are transported is
debated (Lariviere and Julien, 2004). Transport and
spacing are mediated by NF-M and NF-H, whereas
NF-L serves as scaffold to assemble the NF complex
(Ching and Liem, 1993; Lee et al., 1993). In mouse
models, overexpression or loss of one of the three NF
subunits result in disturbance of axonal maturation
(reviewed in Lariviere and Julien, 2004). Simultane-
ous overexpression of all three subunits increases the
axonal diameter (Xu et al., 1996), demonstrating that
functional NF complexes require correct stoichiom-
etry. CMT-linked NF-L mutations affect various
aspects of NF biology, including axonal transport of
mutant NF, transport of mitochondria, anterograde,
and retrograde axonal transport. In addition, some
mutants exert a dominant-negative effect on the trans-
port of wild-type NF and cause fragmentation of the
Golgi apparatus (Brownlees et al., 2002; Perez-Olle
et al., 2002, 2004, 2005). Thus, a generalized axonal
transport defect appears to be responsible for the
observed neuropathy. The nature of the generated
signal(s) causing the prominent myelination defects
that are associated with some NF mutations remains
an interesting subject for future studies.
Heat-Shock Proteins: 27-kDa Protein 1 
and 22-kDa Protein 8
Mutations in the small heat-shock proteins B1
(HSPB1/HSP27) cause dominant axonal CMT2F
and distal hereditary motor neuropathy (Evgrafov
et al., 2004) whereas mutations in B8 (HSPB8/
HSP22) have been described in hereditary motor
neuropathy type 2 (Irobi et al., 2004). These two
HSPs interact with each other suggesting some
common disease mechanisms (Benndorf et al., 2001;
Sun et al., 2004). Two additional members of the
sHSPfamily are associated with diseases in humans,
αA-crystallin mutations (HSPB4) with cataracts, and
αB-crystallin mutations with desmin-related
myopathy (Sun and MacRae, 2005). sHSPs contain
a conserved C-terminal α-crystallin domain that sta-
bilizes target proteins in a nonaggregated folding-
competent state (Lee et al., 1997). In contrast to HSPs
with an ATPase domain, like HSP70, sHSPs are
unable to unfold misfolded proteins. These features
are assumed to form the mechanistic basis why
mutations in sHSPlead to the formation of aggregates
that probably interfere with cellular functions. Inter-
estingly, coexpression of mutated HSPB1/HSP27
with NF-L in cells with no intermediate filaments
resulted in aggregation of NF-L, whereas no such
effect was observed with wild-type HSPB1
(Evgrafov et al., 2004). These experiments are
intriguing and suggest that mutations in HSPB1
may cause alterations in the NF network providing
a potential mechanistic link to NF-L mutations.
However, the hypothesis that HSPB1/HSP27 (and
possibly also HSPB8/HSP22) are controlling the
folding and assembly of NFs in vivo and the
causative relationship of this mechanism for the
resulting disease remains to be substantiated.
Gigaxonin
The functions of actin fibers, MTs, and intermedi-
ate filaments in the cytoskeleton are tightly coupled.
This is illustrated by homozygous mutations found
in gigaxonin leading to giant axonal neuropathy
(GAN) (Bomont et al., 2000; Kuhlenbaumer et al.,
2002). Gigaxonin belongs to a protein family that is
characterized by an N-terminal BTB (broad-complex,
Tramtrack, and Bric a brac) domain and six kelch
repeats. BTB/kelch proteins are organizers of the
cytoskeletal network and closely linked to the ubiq-
uitin degradation pathway (Stogios and Prive, 2004).
Patients with GAN have segmental axonal swellings
characterized by NF accumulations in the cerebellum,
the cerebral white matter, and peripheral nerves
(Bomont et al., 2000). Intermediate filaments, includ-
ing vimentin, the glial fibrallary acidic protein, and
sometimes keratin, are disordered in diseased tissues
(Mahadevan et al., 2000). Gigaxonin binds, via its kelch
domain, to the MT-associated protein-1B light-chain
(MAP1B-LC) enhancing MT stability, and disease-
associated gigaxonin mutations lead to loss of gigax-
onin–MAP1B-LC interaction probably affecting
MT-dependent axonal transport (Ding et al., 2002).
Gigaxonin also interacts with the E3-ubiquitin ligase
cullin3 like many other BTB-family members (Pintard
et al., 2004). Although speculative at this point, gigax-
onin may bridge the ubiquitin ligase cullin3 to the
potential substrate MAP1B-LC (Pintard et al., 2004).
Kinesin Family Member 1B
MTs serve as tracks that guide directed transport
of vesicles, protein complexes, organelles, and chro-
mosomes as they have a directed polarity with the
growing plus-end in the periphery and the minus-end
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at the centrosome (Howard and Hyman, 2003). Motor
proteins, including dyneins and kinesins (KIFs), drive
these transport processes by hydrolyzing ATP and
converting the energy into mechanical work. Many
KIFs move toward the plus end of MTs whereas the
majority of the dyneins mediate transport to the minus
end. Dynein–dynactin complexes carry out the fast
retrograde transport in motor axons. Mutations in
dynactin, probably affecting its binding to MTs, cause
dominantly inherited motor neuron disease (Puls
et al., 2003), highlighting the importance of this trans-
port pathway in motor neuron axons. KIF-mediated,
plus-end-directed, or anterograde transport in axons
delivers cargo from the neuronal cell body into the
periphery (Hirokawa and Takemura, 2005). A muta-
tion in KIF1B was described in a Japanese family
affected by dominant axonal CMT2A(Saito et al., 1997;
Zhao et al., 2001). The KIF1B gene encodes two dif-
ferent isoforms that are generated by alternative splic-
ing and differ in their C-terminal cargo-binding
domain (Nangaku et al., 1994; Zhao et al., 2001). The
mutation in CMT2A patients is located in the middle
of the ATP-binding site (Zhao et al., 2001) and disrupts
the function of both splice variants. KIF1B-α binds to
mitochondria and mediates mitochondrial plus-end-
directed transport (Nangaku et al., 1994) whereas the
cargo-binding domain of the second splice variant
KIF1B-β associates with synaptic vesicles precursors.
Heterozygous KIF1B-deficient mice display a defect
in transporting synaptic vesicle precursors and suffer
from progressive muscle weakness (Zhao et al., 2001).
These findings, in combination with data demon-
strating that the CMT2Amutation in KIF1B-β is asso-
ciated with decreased ATPase activity and motility,
lead to the suggestion that haploinsufficiency of this
motor protein is the cause of CMT2Aneuropathy, likely
owing to impaired transport of synaptic vesicle pre-
cursors or affecting neuronal survival (Zhao et al.,
2001). Unfortunately mutations in KIF1B were only
identified in a single family. Yet, the role of KIF1B in
axonal transport was supported by the phenotype of
the heterozygous KIF1B mice (Zhao et al., 2001).
Altered Mitochondrial Dynamics 
in CMT
Fusion of Mitochondria: Mitofusin2 
Mitofusin2 (MFN2) is the second gene mutated in
dominant axonal CMT2A (Züchner, et al., 2004).
MFN2 belongs to the class of large GTPases such as
DNM2. MFN2 is a component of the outer mitochon-
drial membrane and a key regulator of mitochon-
drial fusion (Santel and Fuller, 2001; Rojo et al., 2002).
Together with MFN1, MFN2 forms the tethering com-
plex that brings the outer membranes of two mito-
chondria into close proximity to allow fusion (Koshiba
et al., 2004). Although MFN1 and MFN2 show a high
degree of functional redundancy in cell culture exper-
iments, mice lacking either MFN2 or MFN1 die at
midgestation owing to placental defects (Chen et al.,
2003). Mouse embryonic fibroblasts deficient in MFN1
or MFN2 display an increase of fragmented mito-
chondria, consistent with central roles of these pro-
teins in mitochondrial fusion. The fragmented
mitochondria lose their membrane potential and
show impaired mitochondrial transport (Chen et al.,
2003). Thus, the underlying disease mechanisms of
disease-causing dominant MFN2 mutations might
be alterations of the physiology of mitochondria.
Alternatively, or in addition, impaired mitochondr-
ial transport may cause a deleterious lack of energy
supply in distal parts of axons in CMT2A patients
(Shy, 2004; Züchner et al., 2004). It is tempting to spec-
ulate that the latter mechanism could explain why
mutations in MFN2 and in KIF1B lead to identical
phenotypes, yet no obviously altered mitochondrial
distribution was observed in KIF1B-deficient mice
(Zhao et al., 2001). However, mitochondrial dynam-
ics are a complex system and other contributing fac-
tors to the disease phenotype can be envisaged.
Blocking mitochondrial fusion reduces respiratory
capabilities, interferes with mitochondrial calcium
homeostasis, and renders cells more vulnerable to
apoptotic stimuli (Chen et al., 2005; Neuspiel et al.,
2005; Perfettini et al., 2005; Pich et al., 2005). Inter-
estingly, mutations in another large mitochondrial
GTPase, OPA1, are associated with dominant optic
atrophy (Alexander et al., 2000). Loss of OPA1 disru-
pts mitochondrial integrity leading to cytochrome-c
release (Olichon et al., 2003) and intriguingly, OPA1
functionally cooperates specifically with MFN1 to
mediate the fusion of the inner mitochondrial mem-
brane (Chen et al., 2005; Cipolat et al., 2004). 
Fragmentation/Fission of Mitochondria:
Ganglioside-Induced Differentiation
Associated Protein 1
Mutations in ganglioside-induced differentiation-
associated protein (GDAP)-1 lead to early-onset
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CMT and are a frequent cause of recessive demyeli-
nating, intermediate, and/or axonal forms of CMT
(Baxter et al., 2002; Cuesta et al., 2002; Nelis et al.,
2002). Neurons and Schwann cells express GDAP1,
suggesting that both cell types may contribute to
the mixed features of the disease (Niemann et al.,
2005). GDAP1 is localized in the outer mitochon-
drial membrane (Niemann et al., 2005; Pedrola et al.,
2005) and regulates the mitochondrial network
(Niemann et al., 2005). In contrast to MFN2, GDAP1
induces mitochondrial fragmentation. However,
this effect can be counteracted by active MFN2.
CMT-associated GDAP1-truncations are not tar-
geted to mitochondria and have lost mitochondrial
fragmentation activity. The latter activity is also
strongly reduced for disease-associated GDAP1
point mutations (Niemann et al., 2005). The exact
role of GDAP1 in the regulation of mitochondrial
dynamics remains to be elucidated, particularly how
GDAP1 interacts with the rest of the mitochondrial
fusion/fission machinery. Nevertheless, the CMT-
causing mutation in MFN2 and GDAP1 demon-
strate conclusively that proper regulation of
mitochondrial dynamics is a critical factor for the
proper function of myelinated peripheral nerves.
This notion extends the already earlier recognized
fact that mitochondrial disturbances are a frequent
basis of neurological defects (Bossy-Wetzel et al.,
2003; Chen and Chan, 2004). 
Lamin A/C in CMT
Mutations in lamin A/C (LMNA) cause autosomal-
recessive (AR) CMT2A(De Sandre-Giovannoli et al.,
2002; Tazir et al., 2004). Lamins are ubiquitously
expressed intermediate filament proteins that form
the nuclear lamina. The nuclear lamina is linked to
the inner nuclear membrane via integral membrane
proteins. Together with the nuclear envelop, the
nuclear lamina determines the nuclear shape and
organizes the nuclear pore complexes that allow
transport in and out of the nucleus (Mounkes and
Stewart, 2004). Whereas the chromatin itself orga-
nizes independently, the nuclear lamina can provide
a scaffold to form distinct subcompartments of the
nucleus (Chubb et al., 2002). In this way, the nuclear
lamina influences diverse processes such as DNA
replication, gene expression, nuclear transport,
apoptosis, and intracellular signaling pathways
(reviewed in Mounkes and Stewart, 2004). Given
this diversity of nuclear lamina functions, it is not
surprising that mutations in lamins give rise to a
variety of different diseases including muscular
dystrophies, cardiomyopathies, lipodistrophy,
dysplasia, premature aging (progeria), and AR-
CMT2A. Lamin A/C-null mice are affected by axonal
loss, axonal enlargement, and nonmyelinated large-
caliber axons, somewhat resembling the phenotype
of AR-CMT2A (De Sandre-Giovannoli et al., 2002).
Recently, an intriguing function for lamins A and
C in the protection of cells from physical damage
and in the maintenance of the function of tran-
scription factors required for the differentiation of
adult stem cells has been proposed (reviewed by
Hutchison and Worman, 2004). Particularly, nega-
tively altered protection of neurons from physical
damage owing to mechanical influences might be
related to the disease mechanism in AR-CMT2Abut
conclusive experimental evidence to support this
speculation is missing.
KIAA1985 in CMT
The gene encoding the KIAA1985 transcript is
mutated in recessive demyelinating CMT4C (Senderek
et al., 2003a). This transcript encodes a protein of
unknown function containing Src homology-3 and
tetratricopeptide-repeat motifs. Src homology-3
domains and tetratricopeptide-repeat motifs
mediate assembly of protein complexes but inter-
action partners of KIAA1985 have yet to be
described. Elucidation of the function of KIAA1985
and the potential disease mechanisms in CMT4C
remains a challenge for the future.
Concluding Remarks
Inherited neuropathies were first described by
Charcot, Marie, Tooth and Herringham in 1880s,
before Mendelian inheritance was appreciated. As
the genetics and molecular causes have been unrav-
eled over the past 20 yr, the complexity of these
diseases became apparent. We are just starting to
understand the complex relationships between
genotypes and phenotypes and how disease
mechanisms may converge. As an added benefit,
investigating how the different disease-causing genes
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cause neuropathy provides a direct path to a better
understanding of how axon–Schwann-cell inter-
actions control the development and maintenance
of myelinated nerves. Studying the genetics and
biology of CMT has provided us with numerous
important clues toward our current understanding
of the peripheral nervous system. Several key proteins
have been identified, or functionally confirmed in this
way, and many are still to come, given the numerous
CMT-associated loci where the genes are currently
being identified. Rather than making the situation
more confusing, however, the identification of novel
players has provided us with the first examples of how
these proteins are interconnected in common path-
ways and networks. This includes most notably:
1. the regulation of the development and mainte-
nance of the myelin structure, 
2. protein biosynthesis, sorting, and degradation, 
3. endocytosis, membrane, and vesicle dynamics,
including mitochondria, and 
4. the crucial role of the cytoskeleton. Many of these
processes are dynamically connected within cells
and should not be viewed in isolation. 
In summary, research on CMT has not only lead
to significant progress in our understanding of the
disease mechanisms but also allowed exciting stud-
ies in the cell and molecular biology of peripheral
nerves. Last but not least, such studies have also
provided the basis for first rational treatment
approaches of CMT1A (Sereda et al., 2003; Passage
et al., 2004).
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